Pinteon Therapeutics

Pinteon Therapeutics is a clinical-stage biotechnology company in Newton, Massachusetts developing antibody therapeutics for neurodegenerative disease. Its work centers on cis-pT231 tau, a conformation of the tau protein that is acutely neurotoxic and drives the initiation and spread of tau pathology. The company's lead asset, PNT001, is a monoclonal antibody that has completed a Phase 1 single-ascending-dose study in healthy volunteers and is aimed at tauopathies including traumatic brain injury, chronic traumatic encephalopathy, Alzheimer's disease and progressive supranuclear palsy. Pinteon is a small private company that has raised roughly $52M to date.

PNT001 is described as the only antibody in development that targets cis-pT231 tau specifically, a conformation-selective epitope that lets it neutralize an acutely neurotoxic form of tau rather than binding total tau, which is intended to both blunt acute neurotoxicity and block the propagation of tau pathology between neurons.